Ambea AB (0RNX)
London Stock Exchange · UK · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 186.70 |
|---|---|
| 52-week range | 113.60 – 186.70 |
| Return, 1 month / 3 months | +7.5% / +30.9% |
| Return, 1 year / 3 years | +48.3% / +398.2% |
| Trend | Uptrend |
| RSI (14) | 66 |
| Volatility (1 year) | 32.5% |
| Worst drawdown (1 year) | -19.2% |
| Average daily value traded | 6.84M SEK |
| Dividend yield | 1.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ambea AB is a Swedish care company that provides health and social care services. It runs residential care homes for older people and supported living and disability services through its operating brands. Its customers are mainly municipalities and public authorities in Sweden that commission care, along with the individuals and families who use the services. The company is based in Stockholm and focuses on care delivered in everyday settings across local communities.
Ambea AB trades under the code 0RNX on the London Stock Exchange in UK, with its price quoted in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ambea AB (0RNX) trades on the London Stock Exchange in UK. It last closed at SEK 186.70 on 27 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 206 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 48.3% and over the last three months it rose 30.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 94 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 27.9% | ||
| From 52-week high | 0.0% | ||
| Momentum | 89 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 30.9% | ||
| 6-month return | 37.5% | ||
| 12-month return, skipping the last month | 38.0% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.2% | ||
| Liquidity | 71 · Strong | Trades actively. | |
| Average daily value traded | 6.84M SEK | ||
| Zero-volume days | 10.0% | ||
| Income | 32 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.7% |
|---|---|
| 1 month | +7.5% |
| 3 months | +30.9% |
| 6 months | +37.5% |
| 1 year | +48.3% |
| 3 years | +398.2% |
| 5 years | +239.7% |
Signals
| 50-day / 200-day average | 174.62 / 145.96 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.92 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 May 2026 | SEK 2.6500 |
| 15 May 2025 | SEK 2.2000 |
| 16 May 2024 | SEK 1.5000 |
| 12 May 2023 | SEK 1.2500 |
| 13 May 2022 | SEK 1.1500 |
| 14 May 2021 | SEK 1.1500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.